- Home
- ICU vs HCWB Comparison
ICU vs HCWB Comparison
Compare ICU & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- HCWB
- Stock Information
- Founded
- ICU 2018
- HCWB 2018
- Country
- ICU United States
- HCWB United States
- Employees
- ICU N/A
- HCWB N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- HCWB Health Care
- Exchange
- ICU Nasdaq
- HCWB Nasdaq
- Market Cap
- ICU 10.4M
- HCWB 8.4M
- IPO Year
- ICU N/A
- HCWB 2021
- Fundamental
- Price
- ICU $0.61
- HCWB $4.41
- Analyst Decision
- ICU
- HCWB Strong Buy
- Analyst Count
- ICU 0
- HCWB 1
- Target Price
- ICU N/A
- HCWB $35.00
- AVG Volume (30 Days)
- ICU 19.2M
- HCWB 241.2K
- Earning Date
- ICU 08-12-2025
- HCWB 08-13-2025
- Dividend Yield
- ICU N/A
- HCWB N/A
- EPS Growth
- ICU N/A
- HCWB N/A
- EPS
- ICU N/A
- HCWB N/A
- Revenue
- ICU $428,000.00
- HCWB $1,445,145.00
- Revenue This Year
- ICU $754.07
- HCWB N/A
- Revenue Next Year
- ICU $100.09
- HCWB N/A
- P/E Ratio
- ICU N/A
- HCWB N/A
- Revenue Growth
- ICU N/A
- HCWB N/A
- 52 Week Low
- ICU $0.31
- HCWB $3.55
- 52 Week High
- ICU $9.56
- HCWB $100.80
- Technical
- Relative Strength Index (RSI)
- ICU 41.48
- HCWB 40.10
- Support Level
- ICU $0.52
- HCWB $4.03
- Resistance Level
- ICU $0.83
- HCWB $4.37
- Average True Range (ATR)
- ICU 0.16
- HCWB 0.54
- MACD
- ICU 0.04
- HCWB 0.12
- Stochastic Oscillator
- ICU 50.89
- HCWB 45.31
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.